Gynecologic Cancer | Tumor

CURE’s gynecologic cancer page is an extensive resource of cancer information featuring the latest gynecologic cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on gynecologic cancer.

Moving the Needle for Maintenance Cancer Treatment

September 22nd 2022

Maintenance therapy helps deter undetectable cancer that may exist after initial treatment.

Second-Line Treatment With Libtayo May Improve Long-Term Survival in Subset of Patients With Cervical Cancer

September 14th 2022

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

Lenvima Plus Keytruda Bests Chemotherapy for Advanced Endometrial Cancer

September 12th 2022

Lenvima plus Keytruda improved survival outcomes for patients with pretreated advanced endometrial cancer, according to recent clinical trial data.

Rubraca Staves Off Disease Progression Better Than Chemotherapy in BRCA-Mutant Relapsed Ovarian Cancer, Research Shows

September 9th 2022

Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.

Cervical Cancer Survivor Donates Embryos to Fellow Survivor to Help Fulfill Dream of Motherhood

August 25th 2022

Cervical cancer survivor Ginny Marable heard about a story of a fellow cervical cancer survivor, Tamika Felder, not being able to preserve her fertility. The story moved Marable so much that she and her husband donated their embryos to Felder.

I’m In a Great Place With My Cancer Despite Feeling 25 Years Older Than I Am

August 19th 2022

I am still here fighting, fighting hard and I will continue to do so to make sure I have more graduations, more weddings, and more everything that I can squeeze into my precious time left here on earth.

Rivoceranib-Based Therapy Improves Outcomes in Recurrent Ovarian Cancer

July 20th 2022

Adding Rivoceranib to pegylated liposomal doxorubicin — a type of chemotherapy — improved survival outcomes for patients with platinum-resistant ovarian cancer, according to recent study results.

Trial Launched to Investigate Novel Triplet Therapy in Treatment of Rare Gastric or Esophageal Cancer

July 13th 2022

The manufacturer of one of the cancer treatments announced that it is also participating in clinical trials assessing the safety and efficacy of their product in colorectal and endometrial cancer.

FDA Permits the Study of a Novel Cancer Drug for Multiple Solid Tumors to Continue

June 30th 2022

The study the FDA allowed to continue is investigating the safety and efficacy of the novel cancer drug ACR-368 in patients with endometrial, urothelial and ovarian cancer.

FDA Approves Tafinlar Plus Mekinist for Patients With BRAF V600-Mutant Solid Cancers

June 23rd 2022

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.

It’s No Longer ‘Platinum or Bust’ For Patients With Gynecologic Cancers

June 22nd 2022

The FDA approval of the first poly (adenosine diphosphate-ribose) polymerase, or PARP, inhibitor in the 2010s has drastically changed how patients with gynecologic cancers are treated.

Uncovering New Ways to Make Cancer Surgery Safer

June 21st 2022

The use of newer tools and techniques may be reducing the risk of surgical site infections and other complications in patients receiving treatment for gynecologic cancers.

I Was Blindsided by a Cancer I’ve Never Heard Of

May 24th 2022

I was told that I would miscarry my pregnancy, but continued to feel more pregnant, leading to my molar pregnancy diagnosis — a condition I’ve never heard of before. 

Cancer Trial Hopes to Find New Patient Populations That Will Respond to Already-Approved Drugs

May 19th 2022

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

Cancer Vaccine-Tecentriq Combo Elicits ‘Very Encouraging’ Outcomes in Advanced Cervical Cancer

May 10th 2022

Treatment with an investigational cancer vaccine plus Tecentriq was associated with positive outcomes in patients with heavily pre-treated advanced cervical cancer, according to findings from an interim analysis of a phase 2 trial.

Extraordinary Oncology Nurse, Extraordinary Person

May 7th 2022

Donna MacDonald, B.S.N., RN, OCN, CCM, goes beyond her duties as a nurse to advocate and support her patients.

First-in-Human Trial of an Investigational Cell Therapy for Advanced Gynecologic Cancers Treats First Patient

April 7th 2022

The first patient was dosed in an early-phase trial evaluating the investigational cell therapy DeTIL-0255 for the treatment of advanced ovarian, cervical and endometrial cancer.

Here We Go Again: After Already Overcoming Multiple Obstacles This Year, Another Cancer Treatment Regimen is on My Horizon

April 2nd 2022

The year 2022 has already been filled with obstacles and heartache — as well plans for a new cancer treatment — but I’m putting away the bad thoughts to get ready for the fight ahead of me.

FDA’s Keytruda Approval for Subset of Advanced Endometrial Cancer Provides Patients With a ‘Practice Changing’ Treatment Option

March 29th 2022

Keytruda was well tolerated and demonstrated practice-changing responses with potential for a curative approach in a group of patients with advanced endometrial cancer, according to an expert.

Increased Use of First-Line Maintenance Treatment Is ‘Reassuring’ for Patients With Ovarian Cancer

March 28th 2022

It is essential that patients and providers discuss appropriate options for maintenance therapy after ovarian cancer, one expert explained.

Birthday Reflections on My Cancer Experience: I’m Fighting the Best I Can

March 26th 2022

Today is my birthday, and while I’ve had some unforeseen changes in my cancer treatment lately, I’m grateful to still be here to celebrate.

Imfinzi Fails to Improve Survival in Locally Advanced Cervical Cancer

March 25th 2022

AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.

Intravenous and Direct-to-Abdomen Chemotherapy Plus Avastin Lead to Similar Outcomes in Advanced Ovarian Cancer

March 23rd 2022

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

Treatment With Novel Drug Induces Promising Response Rates in Ovarian Cancer Subgroup

March 22nd 2022

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Zejula-Avastin Combo Improves Outcomes, With ‘No Impact on Quality of Life’ in High-Risk Ovarian Cancer

March 22nd 2022

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

FDA Approves Second Keytruda Indication for Subset of Advanced Endometrial Cancer

March 21st 2022

The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.

Cancer Survivors Obtain Similar Immune Response to HPV Vaccine as General Population

December 16th 2021

The vaccine, which protects patients from seven different strains related to HPV-related cancers, may be considered part of routine oncology care for survivors.

Keytruda Receives FDA Approval for Firstline Treatment of Certain Patients With Cervical Cancer

October 13th 2021

The FDA approved Keytruda for use with chemotherapy with or without bevacizumab, for the treatment of a subset of patients with cervical cancer.

Effects of Early Menopause From Cancer Treatment May Be Eased With Hormone Replacement Therapy

October 6th 2021

Side effects from early-onset menopause from medical treatments may be mitigated with hormone replacement therapy.

FDA Approves Tivdak for Metastatic/Recurrent Cervical Cancer

September 20th 2021

Tivdak is a targeted therapy that showed promising results for patients with pretreated metastatic or recurrent cervical cancer.